Liver cancer, Secondary cancers
Results
Phase 2
This trial looked at a drug called codrituzumab which was previously known as GC33.
It was for people with a type of liver cancer called hepatocellular cancer (HCC) that had spread to other parts of the body (advanced cancer).
HCC is the most common type of liver cancer.
Recruitment start: 2 February 2012
Recruitment end: 3 March 2013
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Paul Ross
Experimental Cancer Medicine Centre (ECMC)
Roche
Last reviewed: 06 Dec 2018
CRUK internal database number: 9367
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
